Failure to induce protection against transplanted mammary tumours by vaccination with the purified murine mammary tumour virus structural proteins GP52 and P28
article
Twelve-week-old female DBAf,(BALB/cxDBAf)Fl(CD2)and GR mice were injected s.c. with the purified mouse mammary tumour virus (MTV)-derived proteins gp52 and p28 wit adjuvant. Twenty days postvaccination, the DBAf mice were challenged i.p. with the MTV-containing L1210 leukaemia; the vaccinated CD2 and GR mice were challenged s.c. with solid primary mammary tumour cells. The vaccinated mice showed no delay in tumour appearance as compared to control animals which were treated with the adjuvant alone. With the leukocyte adherence inhibition assay performed on day 20 postvaccination, it was found that gp52 induced good cellular reactivity; however, factors that block cellular reactivity were also demonstrated in the serum. Antibody titers as determined by an enzyme linked immunoassay were low or negative. MTV disrupted by freezing and thawing provided slight protection in DBAf mice against the growth of the L1210 leukaemia. It is concluded that the immunogenic properties of gp52 are too weak to provide a useful vaccine against transplanted mammary tumours.
Chemicals/CAS: Antibodies, Viral; Viral Proteins; Viral Vaccines
Chemicals/CAS: Antibodies, Viral; Viral Proteins; Viral Vaccines
Topics
virus proteinanimal experimentbreastbreast carcinomacancer graftmousemouse mammary tumor oncovirusAnimalAntibodies, ViralEnzyme-Linked Immunosorbent AssayFemaleImmunity, CellularLeukemia L1210Leukocyte Adherence Inhibition TestMammary Neoplasms, ExperimentalMammary Tumor Virus, MouseMiceMice, Inbred DBANeoplasm TransplantationTransplantation, IsogeneicVaccinationViral ProteinsViral Vaccines
TNO Identifier
228701
ISSN
02775379
Source
European Journal of Cancer and Clinical Oncology, 15(5), pp. 679-684.
Pages
679-684
Files
To receive the publication files, please send an e-mail request to TNO Repository.